Exclusive Summary

• - Core patents expired in 2020–2021; US generics for XR 11/22 mg entered from 2024, opening a global launch window in 2024–2026.
• - RA/UC/PsA together affect >25 million people globally, with 6–9 million needing advanced therapy; once-daily XR meets adherence-driven demand.
• - XR 11/22 mg remains scarce in many markets; a US-registered XR generic offers clear channel differentiation.
• - US‑FDA GMP and US registration enable accelerated reliance pathways across LATAM, Africa, MENA, and SEA.
• - Versus originator, a 50–80% price reduction is achievable, with oral therapy avoiding cold-chain/infusion costs to lower total care spend.